Home
Search results “Ovarian cancer screening standard”
New hope for ovarian cancer
 
03:33
A decade ago, women diagnosed with ovarian cancer had few options for treatment. Surgery, chemotherapy and radiation were standard practice. Those therapies are still in use today, but, thanks to research and new technologies, ovarian cancer patients have additional, and sometimes more effective, options for treatment.
Views: 1734 Mayo Clinic
Michelle’s Ovarian Cancer Story
 
09:02
In this segment, Michelle Fladung reflects back on the symptoms that she encountered prior to her diagnosis with ovarian cancer and encourages other women to pay close attention to their bodies and seek the opinions of their healthcare professionals. Angeles Alvarez Secord, MD, highlights the standard protocol for working with a newly diagnosed ovarian cancer patient within her institution.
Views: 3663 curetoday
Ovarian Cancer: Standards of Care and New Opportunities - Dr. Robert Coleman
 
33:15
This webcast from the 19th Annual Meeting of the Network of Oncology Clinicians and Researchers (NOCR) features comprehensive reviews of the most clinically significant data in different solid tumor types including breast, lung, gastrointestinal, genitourinary, gynecologic, skin, and head and neck cancers. In this video, Dr. Robert Coleman discusses current standards of management and analyzes and interprets the most important new data that has recently modified or has the potential to modify treatment guidelines and recommendations. Earn accreditation for this activity at http://elc.imedex.com/ELC/Activity-Detail.aspx?activityid=6403 © 2012 Imedex, LLC.
Views: 1146 ImedexCME
Healthy Women: Ovarian Cancer
 
02:55
Ovarian cancer is the second most common gynecological cancer and is the leading cause of death from cancer among women in the U.S. Currently, there is no screening test for early detection of ovarian cancer. Standard care is surgery to remove the cancer followed up by chemotherapy. Kathy Fowler discusses testing for ovarian cancer, treatments and prevention with Dr. Shabnam Dadgar.
Views: 164 myMCMedia
Stage I Diagnostics Why Tab Test (Physician)
 
01:29
Just under three decades ago, Dr. O’Brien and his team were instrumental in developing CA125 as an ovarian cancer biomarker, which, until today, has remained the “gold standard” in ovarian cancer monitoring.
Ovarian Cancer After Hysterectomy Is it Possible
 
06:04
Ovarian Cancer After Hysterectomy Is it Possible. Ovarian tumor and hysterectomies. On the off chance that you've had a hysterectomy, you may expect that you can't be determined to have ovarian disease. Much of the time, one or the two ovaries are left set up after a hysterectomy. While having your uterus evacuated diminishes your danger of creating ovarian growth, it is as yet conceivable. Ovarian growth is malignancy that creates from the ovarian cells. The ovaries are the place eggs are created and are the fundamental wellspring of the female hormones estrogen and progesterone. Most ovarian diseases begin in the epithelial cells that cover the external surface of the ovary. Growth can likewise create inside the germ cells that deliver eggs or in the hormone-creating stromal cells. A hysterectomy is a surgical technique in which your uterus is expelled. There are various types of hysterectomies: *partial or supracervical hysterectomy: The uterus is expelled however the cervix is left in place. *total or dish hysterectomy: The uterus and the cervix are evacuated. *radical hysterectomy: The uterus and the cervix are expelled alongside the tissue on the two sides of the cervix and the upper piece of the vagina. In these methods, the ovaries are left set up. Sorts of hysterectomies. As per the American Cancer Society (ACS), having a hysterectomy (notwithstanding when the ovaries are left set up) may decrease the shot of ovarian tumor by 33%. Some of the time the Fallopian tubes and the two ovaries are evacuated amid a hysterectomy. This is known as a respective salpingo-oophorectomy or BSO. Without ovaries, your danger of creating ovarian malignancy is lower, yet there's still some hazard. That is on the grounds that ovarian cells can relocate to the perineum, which is the territory between the vagina and butt. On the off chance that this relocation occurred before your ovaries were expelled, those cells stay behind. These staying ovarian cells can wind up destructive simply like the ovaries can. Also, in the event that they do, it is as yet thought to be ovarian malignancy regardless of whether the ovaries are evacuated before the tumor creates. Growth can likewise create from cells in the peritoneum, the tissue covering the mass of your midriff and keeping in mind that this isn't ovarian malignancy it acts similarly as ovarian tumor and is dealt with comparably. What would i be able to do to avoid having ovarian tumor?. A few ladies are hereditarily inclined to create ovarian tumor. All things considered, you may consider taking preventive measures. One choice is to have your ovaries evacuated. At the point when this is done preventively, it's called prophylactic reciprocal oophorectomy. Without ovaries, you can in any case be determined to have ovarian growth, yet your hazard is altogether lower. In the event that you convey BRCA1 or BRCA2 quality transformations, it can decrease your hazard by 80 to 90 percent, as per the Mayo Clinic. Ladies who convey these qualities are likewise at an expanded danger of bosom growth, so expelling the ovaries before menopause can likewise bring down your danger of hormone-positive bosom tumors. What are the side effects of ovarian malignancy?. Regardless of what kind of hysterectomy you have, you should even now have standard examinations. In any case, there's no normal screening test for ovarian malignancy. Indications of ovarian malignancy can appear to be fairly dubious and gentle at first. Some basic side effects include: All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Views: 1776 Natural Health Care
Ovarian Cancer: Progression and Treatment Options
 
04:41
Dr. Matt McDonald discusses the progression of ovarian cancer and how it is treated. Matt McDonald, MD: Unfortunately in this day and age, the majority of ovarian cancers present at the late stage. Statistically 80% of all ovarian cancers present at an advanced stage either stage 3 or 4. Treatment options for those patients usually requires a combination of a surgery and chemotherapy. New advances in ovarian cancer at this point in time really rely upon what we call adjuvant treatment for ovary cancer and what I mean by that is surgery for ovarian cancer as for several, several decades, its main goal is to what we call surgically remove the cancer and what that means is remove all of the macroscopic or all of the disease that we can see or touch at the time of surgery. Many times we can't remove every single piece of cancer that we can see or feel, but the goal is to leave as little a nodule of cancer behind following surgery and what we strive to do is leave any cancer behind that will be smaller than 1 cm that's the goal and from a surgical standpoint that may require removal of parts of the intestinal tract or urinary tract, etc. The surgery's goal is to remove the large pieces of cancer and leave the smallest amount of residual tumor behind as we can and that's what chemotherapy is for. Chemotherapy works better on small implants of cancer than it does on large implants of cancer. For many patients, we are employing something called intraperitoneal chemotherapy which is when a patient receiving chemotherapy receives a combination of some intravenous chemotherapy which is a standard traditional approach and some patients will receive a combination where they also receive intraperitoneal chemotherapy or a lot of patients consider this a belly wash chemotherapy where there is a port implanted in the abdomen where we infuse chemotherapy directly into the abdominal cavity and in patient that can tolerate and be administered intraperitoneal chemotherapy, it has been shown that these patients actually do better and have a longer survival rate. And so on this day and age that's what most of us strive to do is to have an excellent surgical result followed by a combination intravenous and intraperitoneal chemotherapy. The challenge to the medical environment is to catch ovarian cancer at an earlier stage and there are some new blood tests that are doing a better job with that than we did ten years ago. There are some new screening algorithms or triage algorithms for an ovarian mass that help patients get to a trained professional such as GYN oncologist for their initial operation which in this time still is the most important aspect of a woman's care with ovarian cancer is that her initial diagnosis and initial management is performed by a GYN oncologist. Most notably there are some blood tests. One's called the OVA 1, which is a blood test that screens for five different analytes in a woman's blood to help us dictate whether or not an ovarian mass is cancer or not and that test does do a better job than some of the other more traditional approaches that we use. Again another challenge to women that have been found to have an ovarian mass is to definitely seek out the right physician. The good news is a vast majority of an ovarian mass that is seen on CT scan or ultrasound is benign. It is not a cancer, the vast majority of a time. The challenge for a medical team is to weed out who are those cancers and who is not and certainly seek second opinions, seek out GYN oncologists, if you have an ovarian mass for a second opinion or a surgical consultation, because it's important that you get the best preoperative evaluation in the event that it is a cancer that you are taking care of by the right medical professional. Learn more about Dr. McDonald: http://presbyteriangyncancer.org/?id=5013&sid=123
Views: 10263 Best Doctors
British institute develops new cancer screening test
 
01:49
Low cost blood test to detect and assess the efficacy of cancer treatment. Cambridge research institute developed a method that's capable of detecting the most common forms of cancerous cells without surgery or biopsy, making it safer and cheaper. This innovative method is a simple blood test that could identify defective fragment of DNA shed into the bloodstream by cancer cells as they die. The test is being dubbed as a 'liquid biopsy', and it can follow up on the progress of the tumor and its response to the treatment. Tim Forshaw one of the researchers at Cambridge research institute explains that many sensitive tests have been developed to look for one or just a few changes in genes that cause cancer, but what we have been able to do is screen for many of the potential changes, which would not be possible previously. In fact, researchers sequenced 20,000 possible mutations in six cancer-related genes, a technique to read genetic code, to look for genetic faults in the bloodstream and are not picked up by current screening methods. This is the first time entire genes have been analyzed from a blood samples given by 20 women with ovarian cancer. Doctor Mohamed Murtaza a leading researcher at the cancer institute said: this type of blood test has the potential to revolutionize the way cancer diagnosed and treated, adding: as more genetic faults are discovered in different type of cancer, more treatment will be developed to address them. Once we have a catalogue of such faults we could actually screen patients for them just by this simple blood test and potentially address them with one of many drugs. This low cost blood test could play a major role in fighting cancer and in the near future patients could be given treatments based on the results of this quick blood test rather than having a tissue sample surgically removed for analysis. By: Mostapha Zarou Al Arabiya, London
Elly Mayday talks about the signs and symptoms of Ovarian Cancer
 
03:00
Our dear friend and model Elly Mayday was diagnosed last Spring with Ovarian Cancer. She had suffered through many years of painful symptoms that often masked themselves as something else. Ovarian Cancer is called the 'silent killer' for a reason...signs and symptoms are often ignored because they appear to be something else. You know your body better than anyone else...if something does not feel right to you and these symptoms don't go away...push for more testing!
Views: 34301 Forever Yours Lingerie
Are you at risk for ovarian cancer?
 
06:19
Are you at risk for ovarian cancer? by http://health.india.com/. Find out what signs you need to look out for while testing for ovarian cancer. For more information check out http://health.india.com/diseases-conditions/are-you-at-risk-for-ovarian-cancer/.
Views: 170 TheHealthSite.com
Ovarian Cancer Decisions: Treatment Versus Maintenance
 
04:52
Angeles Alvarez Secord, MD, and her patient, Michelle Berke, discuss ovarian cancer treatment versus maintenance. Dr. Secord explains how PARP inhibitors work.
Views: 449 OncLiveTV
Emerging treatment options for platinum-sensitive ovarian cancer
 
10:11
Emerging treatments for patients with cancer: practical guidelines and expert insights Part 4: Emerging treatment options for platinum-sensitive ovarian cancer Domenica Lorusso Gynaecology Oncology Unit, National Cancer Institute, Milan, Italy Coverage of the satellite symposium session "Emerging treatments for patients with cancer: practical guidelines and expert insights" presented at the European Society for Medical Oncology (ESMO) 2017 Congress on Monday 11 September 2017 in Madrid, Spain. The symposium was supported by Tesaro, who provided this video coverage.
Cancer screening -- what you should know
 
14:58
Download from iTunes: https://itunes.apple.com/us/podcast/cancer-screening-what-you/id431848216?i=307417741 The standard screenings for cancer are for breast, cervical, prostate and colon. For those in a high-risk category, lung, ovarian and liver cancer screenings may be recommended. Therese Bevers, M.D., medical director of Cancer Prevention at MD Anderson Cancer Center, discusses MD Anderson's cancer screening recommendations and explains the conflicting cancer screening reports.
NEOADJUVANT CHEMOTERAPY IN OVARIAN CANCER
 
06:33
Approximately 70% of women with epithelial ovarian cancer (EOC) are diagnosed with advanced stage disease, which is associated with high morbidity and mortality. The standard approach to treating patients with advanced EOC remains primary debulking surgery (PDS) followed by chemotherapy. EOC is one of the most sensitive of all solid tumors to cytotoxic drugs, with over 80% of women showing a response to standard chemotherapy combined with taxane and platinum. Furthermore, residual disease is a major prognostic factor for survival. On the basis of the clinical features, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is considered to be an alternative treatment option to standard treatment in patients unable to undergo complete resection during PDS
Views: 90 TheDanAcademy
Cervical Cancer Screening & Diagnosis | Memorial Sloan Kettering
 
03:29
To learn more about ovarian cancer treatments, please visit http://www.mskcc.org/ovariancancer Like us on Facebook: http://www.facebook.com/sloankettering Follow us on Twitter: http://twitter.com/sloan_kettering The Pap smear is the gold standard screening test for diagnosing cervical cancer. Memorial Sloan Kettering experts discuss the importance of annual Pap smear tests and how cervical cancer is diagnosed. {partial transcript} Can we talk a little bit about cervical cancer? Worldwide it’s significant problem. It’s a bigger problem in this country, thanks to the PAP test. Can you let me know how you see this becoming a real cancer problem as opposed to something that is treated when it’s still in it’s pre-cancerous stage. Fortunately, the pap smear is a very effective tool for the cervix. We have to remember that we are not screening the uterus that sits above it, it’s not testing anything related to the status of the ovaries or fallopian tubes, and it’s truly a screening test for the cervix. The reason it’s such an effective screening tool is because it will pick up abnormal cells of the cervix before they have the opportunity to become invasive cancers.
Doctor is In: Cervical Cancer Screenings
 
05:25
The standard Pap smear is the current method of detecting Cervical Cancer. However, new recommendations from the FDA could change how women are tested for abnormalities. To learn more about Cervical Cancer screenings, watch Scot Ackerman, M.D. discuss these new developments on First Coast Living.
The Ultimate Guide to Ovarian Cancer by Dr. Benedict Benigno
 
02:01
Twenty-five thousand American women will get ovarian cancer this year. No screening test exists for this disease, and the symptoms are often vague and mistaken for other illnesses. This cancer is almost always diagnosed in advanced stages, thus requiring extensive surgery and heavy doses of chemotherapy. The recurrence rate is close to 80%, which means most ovarian cancer patients will need additional chemotherapy and sometimes more surgery. In this breakthrough book, Dr. Benedict B. Benigno offers a compassionate, easy-to-understand in-depth look into standard and out-of-the-box ovarian cancer treatments and a thorough examination of the basic science research that will eventually cause a revolution in the way all cancers will be treated. His own patient experiences are interwoven with the stories of survivors who beat the odds. The evolution of a simple, new diagnostic test is described in detail-a test which may prove to be 100% accurate and which may offer women a way to be screened for ovarian cancer when it is at its earliest stage. The cure rate for a stage one ovarian cancer is over 90%! In this book you will: • Learn what symptoms to look for to help diagnose ovarian cancer earlier. • Get clear facts about current modalities of diagnosis and treatment. • Gain an insight from a board certified gynecologic oncologist into new forms of therapy not yet standard of care for ovarian cancer. • Discover how basic science is the key to new ovarian cancer therapy and why molecular biologists will soon replace oncologists. • Find out how advances in genetic research will eradicate many current forms of cancer treatment. The Ultimate Guide to Ovarian Cancer is the one book you want to read if your life has been even remotely touched by ovarian cancer. Published by Sherryben Publishing with "The Ultimate Book Coach" team http://UltimateBookCoach.com
Views: 733 Kristen Eckstein
Part I - Ovarian Cancer: A Survivor Speaks
 
08:50
An inspirational story of triumph over ovarian cancer. Dr. Lisa Anzisi shares her journey from diagnosis, treatment, survival and advocacy!
Views: 26167 Affinity Health Plan
Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer
 
01:13
Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
Views: 219 OncLiveTV
New Test Personalizes Ovarian Cancer Treatment
 
03:13
When doctors treat ovarian cancer patients, they know that at least 20 percent will not respond to standard treatment. A new test designed by a Pittsburgh-based company lets doctors predict which ovarian cancer patients will not benefit from standard treatment, and pick the best combination of drugs to kill the cancer. Allegheny Health Network gynecologic oncologist Dr. Thomas Krivak tells KDKA-TV that each person's cancer has characteristics unique to that person. ChemoFX, designed by South Side-based Precision Therapeutics, lets Dr. Krivak determine which patients will not respond to platinum-based therapy and give them more effective, targeted treatment earlier in the course of this insidious disease.
HIPEC FOR OVARIAN CANCER
 
01:30
A treatment used for other cancers may make a difference for women with advanced ovarian cancer
Views: 86 Ivanhoe Web
TRACO 2014 - Ovarian cancer; Immune checkpoints
 
01:39:48
TRACO 2014 - Ovarian cancer; Immune checkpoints Air date: Monday, September 29, 2014, 4:00:00 PM Category: TRACO Runtime: 01:57:59 Description: TRACO Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in development and implementation of many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics. For more information go to http://ccr.cancer.gov/careers.courses Author: C.Annunziata; M. Merchant Permanent link: http://videocast.nih.gov/launch.asp?18646
Views: 149 nihvcast
AACR 2009: Ovarian cancer biomarkers
 
04:17
Daniel W. Cramer, M.D., Sc.D., professor of obstetrics and gynecology, Brigham and Womens Hospital, Harvard Medical School, presents at AACR 2009: Phase III Validation of Ovarian Cancer Biomarkers in Pre-Diagnostic Specimens from the PLCO Screening Trial
Views: 363 ecancer
5 Warning Signs Of Endometrial Cancer, Every Woman Should Know | Herbs Cures
 
03:52
in this video i am explaining 5 Warning Signs Of Endometrial Cancer and Every Woman Should Know about this cancer. https://tinyurl.com/y7sflygf APK Download Ovarian Cyst Miracle Top Ovarian Cysts Site On Cb -Visit This Link - http://bit.do/dw7sW The lining of your uterus, your endometrium, is like a garden bed where a pregnancy can be planted. But other things sometimes grow there, too—including cancerous cells. Endometrial cancer affects more than 635,000 women in the U.S., but there's no standard screening test designed to catch it. "Pap smears don't check for or find endometrial cancer, and most women who get it have normal Paps," says Nita Karnik Lee, MD, associate professor of obstetrics and gynecology at the University of Chicago Medicine. In order to detect the disease, your doctor would have to order a transvaginal ultrasound or CT scan (along with a biopsy)—which of course isn't standard or advisable unless there's a strong reason to suspect you might have cancer. Ovarian Cyst Miracle Top Ovarian Cysts Site On Cb -Visit This Link - http://bit.do/dw7sW Dropping pounds for no reason, If you're experiencing this symptom, it may mean your body's been dealing with a problem for a long time. "Weight loss is rare unless it's more advanced cancer," says Lee. If the numbers are plummeting every time you step on a scale, especially if you have other gynecological symptoms, see your doctor ASAP. 5 Warning Signs Of Endometrial Cancer, Every Woman Should Know 5 Warning Signs Of Endometrial Cancer, Every Woman Should Know Ovarian Cyst Miracle Top Ovarian Cysts Site On Cb -Visit This Link - http://bit.do/dw7sW For Weight Loss : https://tinyurl.com/jcdt89t Other Educational Topics are below ! Benefits and Side Effects of Lemon Water : https://youtu.be/8PNC1jZtDnM _______________________________________ 5 Warning Signs Your Appendix Might Burst : https://youtu.be/Du7EUCqmjDw _______________________________________ 5 Warning Signs Of Endometrial Cancer, Every Woman Should Know : https://youtu.be/eJC3_-t_MTs _______________________________________ Most Effective Health Benefits Of Raisins : https://youtu.be/6bDEmI47RTw ________________________________________ curry leaves - Health Benefits Of Curry Leaves : https://youtu.be/0LtMr5hyz-w ________________________________________ How to Heal Cavities and Tooth Decay Naturally with These Home Remedies : https://youtu.be/5GGvISkcaKA _________________________________________ Kidney Cleansing Drinks - Cleansing the Kidneys With a Few Sips : https://youtu.be/2pck8WkxXik ____________________________________ The 10 Second Trick That Can Help You Lose Weight : https://youtu.be/2_X8Vxd9dBU _____________________________________ Avoid these nervous habits that hurt your health : https://youtu.be/U-DamuveUPo _____________________________________ 5 Reasons of Gaining Belly Fat – Easy weight loss : https://youtu.be/qX0-k40zIM0 _____________________________________ Weight Loss - Cancer Prevention - Heart Health with Marrow : https://youtu.be/m5O5s_1FtCU _____________________________________ 5 Surprising Foods That Will Help You Sleep All Night Long : https://youtu.be/qzw1biLETGI _____________________________________ 8 GOOD HABITS YOU MUST ADOPT ASAP FOR YOUR BODY SHAPE : https://youtu.be/NqOyZXr4Em8 _____________________________________ For more recipes and tips, subscribe to the channel! Disclaimer: The materials and the information contained on Natural Cures channel are provided for general and educational purposes only and do not constitute any medical, legal or other professional advice on any subject. None of the information in our videos is a substitute for a diagnosis and treatment by your health professional. Always seek the advice of your physician or other qualified health provider to starting any new diet or treatment and with any questions you may have regarding a medical condition. If you have or suspect that you have a medical problem, promptly contact your health care provider. Images licensed under CC: www.pixabay.com www.flickr.com commons.wikimedia.org www.pexels.com www.publicdomainpictures.net en.wikipedia.org Some images downloaded from shutterstock.com. #Woman #Endometrial #Cancer
Views: 178438 Herbs cures
Ovarian Cancer: Progression and Treatment Options
 
04:41
Unfortunately in this day and age, the majority of ovarian cancers present at the late stage. Statistically 80% of all ovarian cancers present at an advanced stage either stage 3 or 4. Treatment options for those patients usually requires a combination of a surgery and chemotherapy. New advances in ovarian cancer at this point in time really rely upon what we call adjuvant treatment for ovary cancer and what I mean by that is surgery for ovarian cancer as for several, several decades, its main goal is to what we call surgically remove the cancer and what that means is remove all of the macroscopic or all of the disease that we can see or touch at the time of surgery. Many times we can't remove every single piece of cancer that we can see or feel, but the goal is to leave as little a nodule of cancer behind following surgery and what we strive to do is leave any cancer behind that will be smaller than 1 cm that's the goal and from a surgical standpoint that may require removal of parts of the intestinal tract or urinary tract, etc. The surgery's goal is to remove the large pieces of cancer and leave the smallest amount of residual tumor behind as we can and that's what chemotherapy is for. Chemotherapy works better on small implants of cancer than it does on large implants of cancer. For many patients, we are employing something called intraperitoneal chemotherapy which is when a patient receiving chemotherapy receives a combination of some intravenous chemotherapy which is a standard traditional approach and some patients will receive a combination where they also receive intraperitoneal chemotherapy or a lot of patients consider this a belly wash chemotherapy where there is a port implanted in the abdomen where we infuse chemotherapy directly into the abdominal cavity and in patient that can tolerate and be administered intraperitoneal chemotherapy, it has been shown that these patients actually do better and have a longer survival rate. And so on this day and age that's what most of us strive to do is to have an excellent surgical result followed by a combination intravenous and intraperitoneal chemotherapy. The challenge to the medical environment is to catch ovarian cancer at an earlier stage and there are some new blood tests that are doing a better job with that than we did ten years ago. There are some new screening algorithms or triage algorithms for an ovarian mass that help patients get to a trained professional such as GYN oncologist for their initial operation which in this time still is the most important aspect of a woman's care with ovarian cancer is that her initial diagnosis and initial management is performed by a GYN oncologist. Most notably there are some blood tests. One's called the OVA 1, which is a blood test that screens for five different analytes in a woman's blood to help us dictate whether or not an ovarian mass is cancer or not and that test does do a better job than some of the other more traditional approaches that we use. Again another challenge to women that have been found to have an ovarian mass is to definitely seek out the right physician. The good news is a vast majority of an ovarian mass that is seen on CT scan or ultrasound is benign. It is not a cancer, the vast majority of a time. The challenge for a medical team is to weed out who are those cancers and who is not and certainly seek second opinions, seek out GYN oncologists, if you have an ovarian mass for a second opinion or a surgical consultation, because it's important that you get the best preoperative evaluation in the event that it is a cancer that you are taking care of by the right medical professional. Learn more about Dr. McDonald: http://presbyteriangyncancer.org/?id=5013&sid=123
Views: 130 Best Doctors
Chemotherapy Regimens for Ovarian Cancer
 
06:13
In this segment, Maurie Markman, MD; Michael J. Birrer, MD, PhD; Warner K. Huh, MD; and James Tate Thigpen, MD, review the various chemotherapy regimens used in the management of ovarian cancer.
Views: 737 OncLiveTV
Robotic Surgery for Gynecologic Cancers
 
54:30
Robotic Surgery for Gynecologic Cancers This talk focuses on the very current robotic surgical techniques used for treating ovarian, endometrial and cervical cancers and its advantages and outcomes. Speaker: Amer Karam, MD, Associate Clinical Professor, Associate Director Division of Gynecologic Oncology, Stanford Hospital & Clinics Learn more: http://stanfordhealthcare.org/stanford-health-now/health-library-videos/gynecologic-robotic-surgery.html http://stanfordhealthcare.org/medical-clinics/gynecologic-cancer-program.html Visit: http://stanfordhealthcare.org/
Views: 2262 Stanford Health Care
BRCA Mutation Carriers at Risk for Ovarian Cancer
 
01:25
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com, https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn , ,https://plus.google.com/u/0/+AlexandrosGSfakianakis , https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ , https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA , https://twitter.com/g_orl?lang=el, https://www.instagram.com/alexandrossfakianakis/, Cancers, Vol. 10, Pages 57: Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision by Kelsey Lewis via Cancers Cancers, Vol. 10, Pages 57: Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision Cancers doi: 10.3390/cancers10020057 Authors: Kelsey Lewis Karen Lu Amber Klimczak Samuel C. Mok Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.
Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
 
01:50
Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer.
Views: 217 Targeted Oncology
Advances in the Management of Advanced and Relapsed Ovarian Cancer
 
24:20
Filmed on location in Las Vegas during the 21st Annual NOCR Meeting, this webcast is part of a series that provides expert discussions from physicians and researchers from around the USA reviewing current standards of management and analyzing the most important new data that has the potential to modify treatment guidelines. In this presentation, Dr. Bradley J. Monk discusses the latest advances in the management of advanced and relapsed ovarian cancer. © 2015 Imedex, LLC.
Views: 273 ImedexCME
Ovarian cancer progression and treatment options
 
04:41
Dr. Matt McDonald discusses the progression of ovarian cancer and how it is treated. Matt McDonald, MD: Unfortunately in this day and age, the majority of ovarian cancers present at the late stage. Statistically 80% of all ovarian cancers present at an advanced stage either stage 3 or 4. Treatment options for those patients usually requires a combination of a surgery and chemotherapy. New advances in ovarian cancer at this point in time really rely upon what we call adjuvant treatment for ovary cancer and what I mean by that is surgery for ovarian cancer as for several, several decades, its main goal is to what we call surgically remove the cancer and what that means is remove all of the macroscopic or all of the disease that we can see or touch at the time of surgery. Many times we can't remove every single piece of cancer that we can see or feel, but the goal is to leave as little a nodule of cancer behind following surgery and what we strive to do is leave any cancer behind that will be smaller than 1 cm that's the goal and from a surgical standpoint that may require removal of parts of the intestinal tract or urinary tract, etc. The surgery's goal is to remove the large pieces of cancer and leave the smallest amount of residual tumor behind as we can and that's what chemotherapy is for. Chemotherapy works better on small implants of cancer than it does on large implants of cancer. For many patients, we are employing something called intraperitoneal chemotherapy which is when a patient receiving chemotherapy receives a combination of some intravenous chemotherapy which is a standard traditional approach and some patients will receive a combination where they also receive intraperitoneal chemotherapy or a lot of patients consider this a belly wash chemotherapy where there is a port implanted in the abdomen where we infuse chemotherapy directly into the abdominal cavity and in patient that can tolerate and be administered intraperitoneal chemotherapy, it has been shown that these patients actually do better and have a longer survival rate. And so on this day and age that's what most of us strive to do is to have an excellent surgical result followed by a combination intravenous and intraperitoneal chemotherapy. The challenge to the medical environment is to catch ovarian cancer at an earlier stage and there are some new blood tests that are doing a better job with that than we did ten years ago. There are some new screening algorithms or triage algorithms for an ovarian mass that help patients get to a trained professional such as GYN oncologist for their initial operation which in this time still is the most important aspect of a woman's care with ovarian cancer is that her initial diagnosis and initial management is performed by a GYN oncologist. Most notably there are some blood tests. One's called the OVA 1, which is a blood test that screens for five different analytes in a woman's blood to help us dictate whether or not an ovarian mass is cancer or not and that test does do a better job than some of the other more traditional approaches that we use. Again another challenge to women that have been found to have an ovarian mass is to definitely seek out the right physician. The good news is a vast majority of an ovarian mass that is seen on CT scan or ultrasound is benign. It is not a cancer, the vast majority of a time. The challenge for a medical team is to weed out who are those cancers and who is not and certainly seek second opinions, seek out GYN oncologists, if you have an ovarian mass for a second opinion or a surgical consultation, because it's important that you get the best preoperative evaluation in the event that it is a cancer that you are taking care of by the right medical professional.
Views: 152 Best Doctors EMEAA
Cytoreductive Surgery for Ovarian Cancer
 
06:43
In this segment, Maurie Markman, MD, Warner K. Huh, MD, James Tate Thigpen, MD, Michael J. Birrer, MD, PhD, and Robert A. Burger, MD, discuss cytoreductive surgery for patients with ovarian cancer.
Views: 485 OncLiveTV
Stanford Physicians on Controversies in Screening for Women's Cancer
 
01:29:34
Controversies in Screening for Women's Cancer Recent changes announced for screening guidelines for breast and cervical cancers created a media firestorm that confused women and divided physicians and cancer groups. Physicians in the Breast and Gynecologic Oncology Programs that comprise the Stanford Women's Cancer Program have extensive expertise in the area of screening for women's cancer. These physicians highlight the controversial issues and review the data upon which the recommendations were made. Speakers: Robert Carlson, MD; Jonathan S. Berek, MD, MMS; Debra M. Ikeda, MD Learn more: http://stanfordhealthcare.org/stanford-health-now/health-library-videos/womens-cancer-screening-controversies.html http://stanfordhealthcare.org/medical-clinics/womens-cancer-center.html Visit: http://stanfordhealthcare.org/
ESMO 2017 - Day 2 - Focus
 
06:54
Rafal Dziadziuszko comments on the The Pacific Trial and how Immunotherapy is shaping the landscape in advanced lung cancer. Jonathan Ledermann talks about dosing in ovarian cancer chemo. Produced by the European Society for Medical Oncology http://www.esmo.org
The future of cancer research lies behind us | Robert Nagourney, MD | TEDxSoCal
 
18:45
Robert A. Nagourney, MD, is Medical and Laboratory Director at Rational Therapeutics, Inc., in Long Beach, California, and teaches Pharmacology at the University of California, Irvine School of Medicine. He is board certified in internal medicine, medical oncology, and hematology. During his medical oncology fellowship at Georgetown University, Dr. Nagourney confronted aggressive malignancies for which the standard therapies remained highly unsatisfactory. Responding to an unmet need, he pioneered the development of "personalized cancer therapy" applying a laboratory platform to match patients to therapies based on their unique response profiles. With over 20 years experience in human tumor primary culture analyses, Dr. Nagourney has authored numerous manuscripts, book chapters and abstracts. As co-investigator on national cooperative trials, Dr. Nagourney introduced the use of platinum/Gemcitabine doublets in the management of advanced ovarian and breast cancers, treatments that today are used around the world. These native-state microspheroid cancer studies have enabled Dr. Nagourney to explore the fundamental biology of human malignancies toward a new understanding of molecularly targeted cancer therapeutics. Dr. Nagourney resides in Long Beach, California with his wife and two sons. ABOUT TEDx In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Views: 11873 TEDx Talks
BD introduces new Liquid Based Cytology technique to Enableaccurate Cervical Cancer Screening
 
03:20
BD introduces new Liquid Based Cytology technique to Enableaccurate Cervical Cancer Screening BD Life Sciences-Diagnostic Systems, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of BD SurePathTM Direct to Slide. It is a Liquid Based Cytology (LBC) test intended to be used for screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories. Offering a complete LBC solution and characterized by FDA standardized sample collection process, through ease of use, 100% of the collected sample is sent to the lab. Utilizing BD’s proprietary cell enrichment technique, BD SurePath™ Direct to Slide improved slide quality, whilst accommodating the requirements of labs with lower volume testing. BD SurePathTM Direct to Slide is a unique LBC technique that will offer availability of residual sample for conducting important additional follow up tests without the need for repeat sampling. A scientific session with city’s leading Obstetricians /Gynecologist surgeons and pathologists was inaugurated at the campus by Smt Bharathi Reddy, Trustee & CEO Vijaya Group of Hospitals. Traditionally, conventional pap smear, a simple and quick test has been the mainstay for cervical cancer screening. However, this method has limitations in preparation technique and its ability to detect every abnormality, hence the need to move towards a better and efficient technique. As innovation and research continues in battling the increasing burden of cervical cancer, new technologies such as Liquid Based Cytology (LBC) have emerged as superior screening methods. Commenting that cervical cancer can be prevented by screening women systematically through organized population based programmes, Dr. A. Tamilselvi, Consultant Urogynaecologist& Obstetrician, Madras Medical Mission Hospital &Mangai Women’s Health Exclusive, Chennai said, “Liquid Based Cytology is a cervical cancer screening technique which ensures the early detection of precancerous changes of the cervix. This allows timely treatment of the changes and helps in prevention of cervical cancer. This technique is an advanced method of cervical cancer screening which enhances the chances of satisfactory smears, allows better clarity and lesser time in smear interpretation. It is an important step in prevention of cervical cancer and reduction of deaths due to the disease. We as healthcare professionals, are striving to ensure that an increasing number of women undergo screening tests so that the disease is diagnosed at the earliest.” Pavan Mocherla, Managing Director, BD–India added, “Early detection of cervical cancer and its malignant precursors is imperative for survival. BD’s cancer diagnostic capabilities focus on improving health outcomes for patients by providing laboratories with solutions that improve quality, enhance laboratory system productivity and inform medical decisions. In India where women’s health is a priority, we are glad that BD SurePathTM Direct to Slide will be able to enhance the standard of patient care, representing the next milestone in cervical cancer screening.” Cervical cancer is the second most common cancer in the country among women aged between 15 and 44 years. The importance of proactive and periodic screening stems from the fact that cervical cancer is a preventable and curable condition if detected in the asymptomatic stages. Unfortunately, in India there continues to be a major gap in the awareness levels in women regarding screening especially while still asymptomatic. This further results in delayed diagnosis when the cost of the treatment becomes exorbitant. Hence it is critical to understand the advantages of screening and opt for appropriate testing methods
Views: 129 CHENNAIVIEWS
Deconstructing Breast Imaging Options for Sharsheret Webinar
 
19:13
Dr. Lisa Weinstock, Medical Director of Women's Digital Imaging (www.womensdigital.org) explains what you should know about screening for breast cancer: why mammography is still the gold standard; when you need more than mammography; how family history and breast density affect breast cancer screening; the differences between Mammography, Tomosynthesis, Ultrasound, Molecular Imaging and MRI. This video was originally a webinar for Sharsheret, a support group for young Jewish women facing breast and ovarian cancer. For more information about Sharsheret visit www.sharsheret.org. .
New Frontiers In Ovarian Cancer Treatment: Immunotherapy & Combination Therapy
 
19:31
Dr. Kunle Odunsi, Chair, Department of Gynecologic Oncology The M. Steven Piver Professor of Gynecologic Oncology & Executive Director, Center for Immunotherapy, Roswell Park Cancer Institute discusses the role of immunotherapy and combination therapy in ovarian cancer, with Ovarcome. Talk About Ovarian Cancer. TOGETHER, we can Ovarcome!
Bevacizumab in Ovarian Cancer
 
08:15
In this segment, Robert A. Burger, MD, FACOG, FACS; James Tate Thigpen, MD; Warner K. Huh, MD; and Michael J. Birrer, MD, PhD, discuss the use of bevacizumab in ovarian cancer treatment.
Views: 462 OncLiveTV
New developments in fight against ovarian cancer
 
04:13
Approximately 22,000 U.S. women are diagnosed annually with ovarian cancer and sadly, ovarian cancer is the fifth most common cause of cancer death in women. New maintenance treatment options are now available, that have been shown to significantly reduce the risk of ovarian cancer progression or death, and can be used if a patients ovarian cancer has returned following platinum-based chemotherapy. Dr. Robert Holloway, Medical Director, at Florida Hospital discusses these new developments.
Views: 25 KGUN9
Standard 4.6 Monitoring Compliance Evidence-Based Guidelines Commission on Cancer Program Standards
 
03:20
Standard 4.6 requires an annual study conducted by a physician member of cancer committee, that determines if patients have been evaluated and treated in compliance with evidence-based national guidelines. This video series was created to assist you in understanding and interpreting the CoC Standards. The series includes an introduction video, two videos describing the Eligibility Requirements and an additional 26 individual videos describing select standards. Each video begins with the definition of the standard, describes the requirements for meeting the standard and concludes with best practice information. We hope that you and other members of your cancer committee find these videos useful as your cancer program works to implement and maintain compliance with the CoC Standards. If you or members of your team require additional education on these standards, be sure to visit the CoC Online Education Portal at http://eo2.commpartners.com/users/acs/ to view more in depth educational webinars on the CoC Standards and survey process.
Views: 1351 AmCollegeofSurgeons
In Our Own Words: “No Evidence of Cancer”
 
00:33
Watch medical oncologist Vicky Makker explain how a woman with advanced ovarian cancer was cured after enrolling in a clinical trial at Memorial Sloan-Kettering.
HPV and Caring For Women With Cancer (w/Dr. Lois Ramondetta) | Incident Report 177
 
57:28
Dr. Lois Ramondetta, professor of gynecologic oncology at the MD Anderson Cancer Center talks about HPV, new cervical cancer screening and prevention guidelines, end-of-life care in women with cancer, spirituality & yoga, and much more. Links, transcript and more info: zdoggmd.com/incident-report-177 Request an appointment at MD Anderson by calling 1-877-632-6789 or online at https://my.mdanderson.org/RequestAppointment.
Views: 3240 ZDoggMD
Triple Negative Breast Cancer: What you need to know
 
10:06
We teach you why Triple Negative Breast Cancer is threatening. Learn how it is treated, and it's link to the BRCA genetic mutation. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. What exactly is triple negative breast cancer? 2. Will I need Chemotherapy? 3. What are the benefits of Neoadjuvant Chemo? 4. Isn’t Neoadjuvant Chemo recommended more now? 5. Do I qualify for BRCA genetic testing? 6. Should I consider a Clinical Trial? 7. What is “Triple Negative” breast cancer? “Triple Negative” breast cancers are fast growing tumors that more frequently spread beyond the breast to other parts of the body. Because of this, they are a bigger threat to your life than most other types of cancers of similar size with a different receptor pattern. These cancers are called “triple negative” because the three most important breast cancer “receptors” on the surface of the cells are not present (negative). When present, these receptors are used as targets to attack the cancer with medications. When absent, the main medical therapy is chemotherapy. Your Breast Surgeon will know your “receptor pattern” within days after your initial breast biopsy. These results are often not communicated to you early on in your decision process. Although only 15% of breast cancers are “triple negative,” it is imperative that you specifically ask your surgeon immediately, and well before surgery, “What are my receptor results?” “Triple Negative” is treated with Chemotherapy These cancers are often sensitive to chemotherapy and it is offered to almost everyone healthy enough to tolerate it. Chemotherapy is obviously a more intense cancer treatment than hormonal therapy (pills). But unfortunately, since triple negative cancers do not have “Estrogen receptors” (ER negative), hormonal therapy is not helpful at all. The time to cure triple negative cancer is now, not when it recurs later. Chemotherapy and surgery is the standard for treating triple negative breast cancer. Ask about the benefits of “Neoadjuvant Chemo” What is often overlooked are the benefits of offering neoadjuvant chemotherapy for patients with triple negative, “Early-Stage” (I & II) breast cancer. There may be distinct advantages (listed below) to having chemotherapy before surgery, not after surgery if you have a triple negative tumor. The decision to consider neoadjuvant chemotherapy always begins with your breast surgeon. You must address this “cutting edge” treatment option well before surgery to benefit from neoadjuvant chemotherapy. Do not be afraid to ask. This is a very important question. The Potential Benefits of Neoadjuvant Chemo: *Begin life-saving chemotherapy earlier *Reduce the need for a mastectomy *Improve cosmetic outcomes with a lumpectomy *Reduce the need for an “Axillary Dissection” *Allows more time for BRCA genetic testing *More time to think about “lumpectomy vs. mastectomy” *Shows your cancer team if the chemo is working *Can sometimes eliminate all cancer cells before surgery *May reduce the need for radiation after a mastectomy Ask for BRCA Genetic Testing Triple negative breast cancers can be associated with inherited genetic mutations. Any woman who has ever been diagnosed with a triple negative breast cancer at age 60 or younger is at a high risk for carrying the BRCA mutation. If you also have a strong family history of breast or ovarian cancer you are at an even higher risk. Unfortunately, genetic testing is often not offered for triple negative breast cancer patients. It is important to ask for BRCA Genetic Testing in this situation. The BRCA (Breast Cancer) gene is commonly referred to as “The Breast Cancer Gene.” If someone inherits a broken version (mutation) of this gene at conception, they carry a very high lifetime risk of breast cancer and ovarian cancer. African Americans are a higher risk for Triple Negative African American and women of West African descent are at a higher risk of developing triple negative breast cancers than most other ethnic groups. Thirty percent (30%) of all breast cancers in this group are triple negative. Younger women are at a higher risk for Triple Negative Women diagnosed with invasive breast cancer before 40 are at a higher risk for having triple negative disease when compared to older women. Any women diagnosed before the age of 50 qualifies for genetic testing and should consider genetic counseling. Ask if you would benefit from a Clinical Trial New therapies must be studied in clinical trials to make sure they are safe and effective at treating breast cancer. Ask your medical oncologist if they offer or recommend you participate in a clinical trial.
Robotic Surgery for Gynecologic Cancers
 
04:59
Richard Barakat, Chief of Memorial Sloan-Kettering’s Gynecology Service, discusses robot-assisted surgery for gynecologic cancers.
Will new genetic test for breast cancer be a game-changer?
 
01:59
Color Genomics has come up with a saliva kit that tests for two types of gene mutations linked to breast cancer and ovarian cancer. While traditional tests can cost $4,000, this kit only costs $249. But will it be effective? CBS News chief medical correspondent Dr. Jon LaPook reports.
Views: 18479 CBS Evening News
Breast Cancer &  Genetic Testing: Ask Dr. Claudine Isaacs
 
31:24
Dr. Claudine Isaacs is the director of the Clinical Breast Cancer Program at MedStar Georgetown University Hospital. She has also participated in many years of clinical breast cancer research. Here she answers your questions about breast cancer from diagnosis through treatment as well as new advances in the area of breast cancer.Click "Show More" to see the list of questions that link directly to specific answers. http://ow.ly/PxwIE 00-2:20 Meet Dr. Claudine Isaacs 2:24 How do you determine my prognosis for breast cancer? 3:20 What is estrogen receptor positive? 4:06 What is HER2? 5:08 What is triple negative breast cancer? 6:12 Should I have genetic testing if I have a diagnosis of breast cancer? 7:28 If I don’t have a family history of breast cancer then I don’t need genetic testing? 8:20 What are my treatment choices? 9:10 What are some of the side effects of chemotherapy? 10:45 What are some of the side effects of hormonal therapy for breast cancer? 12:25 What side effects should I report to my doctor? 13:44 How is chemotherapy administered for breast cancer? 14:25 What do you recommend for metastatic breast cancer? 15:50 Can I live with metastatic breast cancer? 16:55 How do I know if I’m eligible for a clinical trial? 17:27 Are clinical trials available at all stages of breast cancer? 18:03 Should I change my diet or lifestyle if I have breast cancer? 18:47 What might have increased my risk of getting breast cancer? 19:58 If I have breast cancer what are the risks to my family? 20:35 Will the treatments for breast cancer cause premature menopause or infertility? 21:50 Do men get breast cancer? 22:45 Can a man have a mammogram? 23:03 What are the treatments for men with breast cancer? 23:30 Is the prognosis for men and women different? 24:00 What advancements have been made in the treatment of breast cancer recently? 26:10 Is a man’s breast cancer staged the same way as a woman’s? 26:20 What are the risks for someone with a genetic mutation BRCA1 or BRCA2? 28:30 As a man with the BRCA1 or BRCA2 mutation what would you advise I do? 29:50 Why should I come to MedStar Georgetown for breast cancer treatment? Learn more about breast cancer screening and diagnosis: http://ow.ly/PxxCv
Charles W. Drescher, M.D.
 
01:58
Dr. Charles W. Drescher is a gynecological oncologist at Swedish Medical Center. He focuses on helping women who may be at risk or diagnosed for cancer in the reproductive tract. Dr. Drescher values the importance of being invested in a patients healthcare, and works with patients to help them understand their disease and treament options. Dr. Drescher specialtys include Gynecologic Oncology, Gynecology, and Robotic Surgery. For more information about Dr. Drescher visit http://www.swedish.org/Physicians/Charles-Drescher
Views: 1140 swedishseattle